AstraZeneca ta sami haɓaka ninki biyu don fayil ɗin cutar sankara a ranar Talata, bayan hukumomin Amurka da na Turai sun karɓi ƙa'idodin ƙa'idodin magungunanta, matakin farko na samun amincewar waɗannan magunguna.
Ma'aikacin Anglo-Swedish mai yin magunguna, da MedImmune, sashin bincike da haɓaka ilimin halittu na duniya, sun ba da sanarwar cewa Hukumar Abinci da Magunguna ta Amurka (FDA) ta karɓi takardar lasisin moxetumomab pasudotox, sabon magani don kula da manya marasa lafiya masu gashi mai gashi. cutar sankarar bargo (HCL) waɗanda suka karɓi aƙalla layukan jiyya guda biyu da suka gabata.
FDA ta ba da matsayin "bita na fifiko", wanda aka ba wa magunguna waɗanda, idan an amince da su, za su ba da gagarumin ci gaba a cikin jiyya, ganewar asali, ko rigakafin mummunan yanayi. Ana sa ran yanke shawara a kashi na uku na wannan shekara.
Na dabam, Hukumar Kula da Magunguna ta Turai ta yarda da ƙaddamar da tsari ga Lynparza, wani magani wanda AstraZeneca ke da shi yanzu a cikin haɗin gwiwa na 50:50 tare da Merck, kamfanin magunguna na Amurka, don magance cutar kansar nono da ke yaduwa a wani wuri a cikin jiki ga marasa lafiya da ke da takamaiman. maye gurbi.
Idan an amince, maganin zai zama farkon mai hana PARP don maganin ciwon nono a Turai. PARP wani furotin ne da ake samu a cikin sel ɗan adam wanda ke taimakawa waɗancan sel su gyara kansu idan sun lalace. Ta hanyar dakatar da wannan tsarin gyarawa a cikin ƙwayoyin kansa, masu hana PARP suna taimakawa tantanin halitta ya mutu.
Lynparza a watan Janairu ta zama farkon mai hana PARP da aka amince da ita a ko'ina cikin duniya don cutar kansar nono, lokacin da ta sami nasara a gaba daga hukumomin Amurka.
A cikin sabuwar gwaji, Lynparza ta daɗe tana daɗawa ba tare da samun ci gaba ba idan aka kwatanta da chemotherapy kuma ta rage haɗarin ci gaba ko mutuwa da kashi 42 cikin ɗari.
A cikin 2017 kashi biyar na tallace-tallacen samfuran Astra sun fito ne daga ilimin oncology kuma kamfanin yana tsammanin wannan rabo ya tashi. Hannun jari a cikin rukunin ya rufe 0.6 bisa dari a kan £49.26.
A wani ci gaban kuma, Compugen, wani kamfanin harhada magunguna na Isra’ila, ya ce ya kulla wata yarjejeniya ta musamman ta lasisi da MedImmune, wadda za ta ba da damar samar da kayayyakin rigakafin kamuwa da cutar kansa.
MedImmune yana da hakkin ya haifar da samfurori da yawa a ƙarƙashin lasisi "kuma za su kasance da alhakin duk ayyukan bincike, ci gaba da kasuwanci a ƙarƙashin yarjejeniyar", in ji Compugen.
Kamfanin na Isra'ila zai karɓi $ 10m gabaɗaya kuma ya cancanci karɓar har zuwa $ 200m a cikin haɓakawa, ƙa'idodi da ci gaba na kasuwanci don samfur na farko, da kuma kuɗin sarauta kan tallace-tallacen samfur na gaba.
Anat Cohen-Dayag, babban jami'in gudanarwa na Compugen, ya ce yarjejeniyar "tana ba mu damar samun takamaiman ci gaban kimiyya a cikin shirye-shiryenmu, yayin da muke ci gaba da ciyar da shirye-shiryenmu na jagora zuwa gwaji na asibiti".
Lokacin aikawa: Afrilu-23-2018